Study on Safety and Efficacy of Focused LED-Based Red-Light Therapy in Myopic Adults
Key facts
- Who runs it
- The Hong Kong Polytechnic University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 14 people, planned
- Started
- 8 Oct 2025
- Planned end
- 31 Jul 2026
- Type of study
- Interventional
- Treatments tested
- fLED-based red-light therapy
- Record updated
- 27 January 2026
Who can take part
- Age
- 18 years to 50 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Age 18-50 years
- SE refractions between -0.50 and -6.00 diopters (D)
- Astigmatism of 1.50 D or less
- Best corrected monocular visual acuity better than 20/20 (Snellen equivalent)
- Willingness to provide written informed consent and comply with the treatment protocol
Who cannot take part
- Previous or current use of myopia control interventions (e.g., orthokeratology, low-dose atropine, pirenzepine) within the past 6 months
- Afterimage time > 5 minutes (contraindications to RLRL therapy)
- History of ocular surgeries (e.g., cataract surgery and LASIK/SMILE)
- Strabismus or binocular vision abnormalities in either eye
- Ocular abnormalities in either eye or other systemic abnormalities
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 50 years old?
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This research project is a prospective, single-arm, open-label pilot study designed to evaluate the efficacy and safety of focused LED-based repeated low-level red-light (fLED-RLRL) therapy in myopic adults. The primary objective is to assess whether the therapy can increase choroidal thickness and improve choroidal blood flow. The secondary objective is to evaluate the safety and tolerability of red light therapy in adult myopes.
Read full original descriptionShow less
The study will enroll 14 myopic adults aged 18 to 50 years, with spherical equivalent refractions ranging from -0.50 to -6.00 diopters. Participants will receive home-based fLED-RLRL therapy (wavelength 650 ± 10 nm, power 0.20 mW) twice daily for 3 minutes per session, 5 days per week, over a total of 28 days, combined with single-vision spectacles. The fLED red-light device employs a standard LED semiconductor chip integrated with a total internal reflection (TIR) lens and microlenses to deliver a precise and concentrated beam, enabling accurate focusing of light energy on the target area. A video tutorial will be provided to guide device usage, and support from the research team will be available throughout the study.
Before the treatment, baseline data will be collected from each participant. Baseline and follow-up assessments (days 7, 14, 21, 28) will include comprehensive ophthalmic examinations: visual acuity, intraocular pressure, slit-lamp examination, autorefraction and subjective refraction, optical coherence tomography (OCT), optical coherence tomography angiography (OCTA), and posterior blood flowgraphy. These assessments will monitor structural and functional changes in the retina and choroid, as well as adverse events (e.g., retinal damage, prolonged after-images).
Primary and secondary outcomes will include changes in choroidal thickness, choroidal blood flow, ocular biometric parameters, spherical equivalent refraction, and visual acuity. Additional imaging assessments, such as posterior blood flowgraphy, OCT, and OCTA scans, will also be evaluated.
This pilot study aims to preliminarily explore the safety and efficacy of an fLED red-light therapy system integrated with machine vision for myopia management by analyzing choroidal parameters over a short-term treatment period. By providing a safer alternative to current laser-based therapies, this project seeks to advance the field of myopia treatment, offering a novel solution that aligns with the increasing demand for effective and safe interventions.
The group in the trial
- fLED-based red-light therapyTreatment being tested
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Safety and Efficacy of Focused LED-Based Repeated Low-Level Red-Light Therapy in Myopic Adults: A Single-Arm Pilot Study
- Criteria questions
- Built from NCT07369804, who can take part
- Record updated
- 27 January 2026